Please ensure Javascript is enabled for purposes of website accessibility

Moderna Receives Additional $472 Million to Develop Coronavirus Vaccine

By Cory Renauer – Jul 26, 2020 at 2:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna's contract with the government has been amended to include extra funding for a 30,000-patient phase 3 study.

Moderna's (MRNA -0.55%) lucrative relationship with the U.S. government took another big step forward on Sunday. The Biomedical Advanced Research and Development Authority (BARDA) amended its contract with the clinical-stage biotechnology company for an additional commitment of up to $472 million.

In April, BARDA agreed to a commitment of up to $483 million to support the advancement of Moderna's coronavirus vaccine candidate, mRNA-1273, from phase 1 trials through FDA licensure. The total value of the award was boosted to $955 million to support a 30,000 person phase 3 trial, which is a lot more participants than originally intended.

Doctor checking in samples of blood.

Image source: Getty Images.

Tomorrow, July 27, volunteers in the phase 3 COVE study will randomly begin receiving either two shots of mRNA-1273 spaced 29 days apart, or a placebo. Investigators will mainly be measuring first occurrences of COVID-19, with two long years of observations beginning 14 days after participants receive their second dose.

In addition to running a giant phase 3 trial, Moderna is also manufacturing huge quantities of mRNA-1273 at risk. With help from a collaboration with Lonza (LZAGY -3.51%), the company is on track to begin delivering between 500 million and 1 billion doses annually in 2021.

Moderna's vaccine candidate will be one of the first to begin a phase 3 trial in the U.S., nearly one month after Oxford University began testing AZD1222 in a 5,000-volunteer study in partnership with AstraZeneca (AZN -3.07%). While we've seen results from dozens of patients treated with mRNA-1273, AstraZeneca and Oxford recently published results from a phase 1 trial with 1,077 randomized to receive AZD1222 or a placebo.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$123.64 (-0.55%) $0.68
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.58 (-3.07%) $-1.73
Catalent, Inc. Stock Quote
Catalent, Inc.
CTLT
$76.07 (-3.78%) $-2.99
Lonza Group Ltd Stock Quote
Lonza Group Ltd
LZAGY
$45.03 (-3.51%) $-1.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.